Incidence and outcome of uveitic glaucoma in eyes with intermediate, posterior or panuveitis followed up to 10 years after randomization to fluocinolone acetonide implant or systemic therapy.

To evaluate long-term risk and outcomes of glaucoma in eyes with intermediate, posterior, and panuveitis managed with systemic or fluocinolone acetonide (0.59 mg, “implant”) therapy.

Source: American Journal of Ophthalmology - July 2, 2020 Category: Opthalmology Authors: John H. Kempen, Mark L. Van Natta, David S. Friedman, Michael M. Altaweel, Husam Ansari, James P. Dunn, Susan G. Elner, Janet T. Holbrook, Lyndell L. Lim, Elizabeth A. Sugar, Douglas A. Jabs, for the Multicenter Uveitis Steroid Treatment (MUST) Trial and Tags: Original Articles Source Type: research